 <h1>Ixiaro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>japanese enceph vacc sa14-14-2, inactivated</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about japanese enceph vacc sa14-14-2, inactivated. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ixiaro.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to japanese enceph vacc sa14-14-2, inactivated: parenteral suspension for im use</i></p><p>Side effects include:</p><p>Infants and children 2 months through 11 years of age: Fever, irritability, flu-like symptoms, diarrhea, vomiting, loss of appetite, rash, injection site reactions (pain, tenderness, erythema). </p><p>Adults and adolescents ≥12 years of age: Headache, myalgia, fatigue, influenza-like illness, nausea, injection site reactions (pain, tenderness, erythema, induration). </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to japanese enceph vacc sa14-14-2, inactivated: intramuscular suspension</i></p><h3>General</h3><p>The most common adverse events in adults were injection site reactions, headache, and myalgia.  The most common adverse events in adolescents (12 to under 18 years) were injection site pain and tenderness.  The most common adverse event in children (1 to under 12 years) was fever.  The most common adverse events in infants (2 months to under 1 year) were injection site redness, fever, irritability, and diarrhea.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Redness (17.6%), pain (15%)</p><p><b>Common</b> (1% to 10%): Tenderness, swelling, hardening, induration, edema, pruritus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (11.5%)</p><p><b>Common</b> (1% to 10%): Vomiting, nausea</p><p><b>Frequency not reported</b>: Rectal hemorrhage<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever over 99.9F (23.7%), flu-like symptoms (13.3%), fatigue (11.3%)</p><p><b>Common</b> (1% to 10%): Excessive fatigue</p><p><b>Frequency not reported</b>: Chest pain, orthopedic injuries</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (15.6%)</p><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Febrile convulsions only occurred in patients under 3 years of age, onset was 2 days to over 5 months after vaccination with no apparent temporal clustering.</p><p>One case of multiple sclerosis was reported in adult clinical trials.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Febrile convulsions, multiple sclerosis</p><p><b>Postmarketing reports</b>: Paresthesia, neuritis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pharyngolaryngeal pain, cough<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, rhinitis, upper respiratory tract infection</p><p><b>Frequency not reported</b>: Appendicitis, limb abscess contralateral to injected arm</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Frequency not reported</b>: Dermatomyositis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Disseminated intravascular coagulation after suspected bacterial meningitis leading to death occurred in a 12 year old male patient 4 months after the second dose of this vaccine.</p><p><b>Frequency not reported</b>: Disseminated intravascular coagulation</p><h3>Cardiovascular</h3><p>Myocardial infarction (MI) occurred in one adult patient with a history of MI, 3 weeks after receiving the second vaccine dose</p><p><b>Frequency not reported</b>: Myocardial infarction</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Ovarian torsion</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Loss of appetite</p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Irritability (15.3%)</p><p id="ref_1">1. "Product Information. Ixiaro (Japanese encephalitis virus vaccine SA14-14-2)." Valneva USA, Gaithersburg, MD. </p><h2>More about Ixiaro (japanese enceph vacc sa14-14-2, inactivated)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: viral vaccines</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Japanese Encephalitis Virus Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>